Wire · opportunities
Isembyld Gains FDA Approval for Spinal Muscular Atrophy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
The FDA has approved Isembyld (apitegromab-mstn), a muscle-targeted treatment for spinal muscular atrophy (SMA) in adults and children aged 2 years and older who are already receiving SMN2-targeted treatments. The approval followed positive results from the phase 3 SAPPHIRE trial showing improved motor function with Isembyld.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 12 Sep 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
Muscle-targeted SMA treatments just opened a new market segment in the US. If you build treatments or support services for SMA patients alongside SMN2 therapies, this widens your addressable market and sales channels immediately.
◆ Coverage
9 sources · first reported 12 Sep 2026 · latest 14 Sep 2026
◆ Related on Wire
◆ Topics